Page last updated: 2024-12-10

2-(4-chlorophenyl)-N-[4-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]phenyl]acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're asking about a molecule with the rather lengthy name **2-(4-chlorophenyl)-N-[4-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]phenyl]acetamide**. This is a chemical compound with a specific structure, and its importance lies in its potential as a **research tool**.

Here's a breakdown:

* **Structure:** The compound has a complex structure, including:
* **Aromatic rings:** It contains several benzene rings (phenyl groups) and a furan ring.
* **Amide group:** The acetamide part is a common functional group in organic chemistry.
* **Piperazine ring:** This is a heterocyclic ring system frequently found in pharmaceuticals.
* **Chlorine atom:** The presence of chlorine can influence the compound's properties.

* **Importance in Research:**

* **Potential drug candidate:** The compound's structure hints at its potential to interact with biological targets. Researchers often explore molecules with such structures because they might exhibit:
* **Pharmacological activity:** They could bind to specific receptors or enzymes in the body.
* **Therapeutic potential:** This compound may be a lead compound for developing new drugs to treat various diseases.
* **Chemical probe:** Even if it doesn't become a drug, it could be a valuable tool for studying biological processes.
* **Structure-activity relationship (SAR) studies:** Chemists often synthesize and test a series of related compounds to understand how changes in the molecule's structure affect its biological activity. This compound could be part of such a series.

**To understand the true importance of this specific molecule, you would need more information:**

* **What biological targets is it being investigated for?**
* **What are the preliminary results of research on this compound?**
* **Is it currently being tested in clinical trials?**

Without this additional context, it's hard to say definitively why this particular compound is significant.

Cross-References

ID SourceID
PubMed CID2979368
CHEMBL ID1581838
CHEBI ID121534

Synonyms (16)

Synonym
AKOS000448881
AP-970/43333648
MLS000066717 ,
smr000082108
2-(4-chlorophenyl)-n-{4-[4-(2-furoyl)-1-piperazinyl]phenyl}acetamide
STK398811
2-(4-chlorophenyl)-n-{4-[4-(furan-2-ylcarbonyl)piperazin-1-yl]phenyl}acetamide
CHEBI:121534
MLS002548502
2-(4-chlorophenyl)-n-[4-[4-(furan-2-carbonyl)piperazin-1-yl]phenyl]acetamide
HMS2287O20
SR-01000628321-2
sr-01000628321
CHEMBL1581838
2-(4-chlorophenyl)-n-[4-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]phenyl]acetamide
Q27210090
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency6.30960.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency23.10930.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency23.72460.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency3.98110.180013.557439.8107AID1460
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency1.77830.28189.721235.4813AID2326
IDH1Homo sapiens (human)Potency23.10930.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency7.94330.035520.977089.1251AID504332
DNA polymerase betaHomo sapiens (human)Potency79.43280.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency19.95260.039816.784239.8107AID995
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency47.75480.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency22.38720.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency14.12540.050127.073689.1251AID588590
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency1.99530.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency10.32250.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]